NeoGenomics, Inc. (NEO)

15,13 -0,44 (-2,83 %) À la clôture : 04:00PM EDT

NeoGenomics, Inc.

9490 NeoGenomics Way
Fort Myers, FL 33912
United States
239 768 0600
https://www.neogenomics.com

Secteur(s): Healthcare
Secteur d’activité: Diagnostics & Research
Employés à temps plein: 2 100

Dirigeants clés

Nom	Titre	Payer	Exercé	Année de naissance
Mr. Christopher Michael Smith BSc	CEO & Director	2,86M	S.O.	1963
Mr. Jeffrey S. Sherman M.B.A.	Chief Financial Officer	1,17M	S.O.	1966
Mr. Vishal Sikri	President of Advanced Diagnostics	1,08M	S.O.	1976
Ms. Melody Harris Esq., J.D.	President & COO of Informatics	1,4M	S.O.	1967
Mr. Warren Stone	Chief Commercial Officer	1,42M	S.O.	1973
Mr. Gregory D. Aunan	Chief Accounting Officer	S.O.	S.O.	1969
Ms. Kendra Sweeney	Vice President of Investor Relations & Communications	S.O.	S.O.	S.O.
Ms. Alicia Olivo	Executive VP of Business Development, General Counsel & Corporate Secretary	S.O.	S.O.	1984
Mr. Hutan Hashemi J.D.	Chief Compliance Officer	S.O.	S.O.	1979
Dr. Derek Lyle M.D.	Chief Medical Officer	S.O.	S.O.	S.O.

Les montants ont été établis en date du 31 décembre 2023 et les valeurs de compensation concernent le dernier exercice fiscal clos à cette date. Le terme « rémunération » désigne le salaire, les bonus, etc. Le terme « exercé » est utilisé pour la valeur des options exercées au cours de l’exercice fiscal. Devise exprimée en USD.

Description

NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories. It also provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; and immunohistochemistry and digital imaging testing services to localize cellular proteins in tissue section, as well as to allow clients to visualize scanned slides, and perform quantitative analysis for various stains. In addition, the company also provides molecular testing services, which focus on the analysis of DNA and/or RNA, and the structure and function of genes at the molecular level; morphologic analysis, which is the process of analyzing cells under the microscope by a pathologist for the purpose of diagnosis; and testing services in support of its pharmaceutical clients' oncology programs covering discovery and commercialization. NeoGenomics, Inc. was founded in 2001 and is headquartered in Fort Myers, Florida.

Gouvernance d’entreprise

L’ISS Governance QualityScore de NeoGenomics, Inc. en date du 1 mai 2024 est 7. Les scores principaux sont Audit : 5; Société : 2; Droits des actionnaires : 3; Compensation : 10.

Résultats de gouvernance d’entreprise offerts par Institutional Shareholder Services (ISS). Les résultats indiquent un rang décile par rapport à l’indice ou à la région. Un résultat décile de 1 indique un risque de gouvernance faible, tandis que 10 indique un risque de gouvernance élevé.